A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

NCT05407519 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
40
Enrollment
OTHER_GOV
Sponsor class

Conditions

Interventions

Sponsor

Anhui Provincial Hospital

Collaborators